Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
JAMA
|
November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
The Lancet. Oncology
|
December 11, 2017
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Breast (Edinburgh, Scotland)
|
January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Nature
|
September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer
Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
JAMA
|
November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
The Lancet. Oncology
|
December 11, 2017
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Breast (Edinburgh, Scotland)
|
January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Nature
|
September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer
Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Page
of 9